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1. General Methods 
 
All chemicals and solvents were purchased from Acros Organics, Alfa Aesar, AstaTech, Oakwood 
Chemical, or Sigma-Aldrich. Chemicals were used without further purification.  
 
Reaction progress was monitored by analytical thin-layer chromatography (TLC) and 1H NMR 
spectroscopy. TLC analyses were performed using E. Merck silica gel 60 F254 pre-coated plates 
(250 µm). A handheld 254 nm UV lamp and potassium permanganate staining solution (with light 
heating) were used for detection. 
 
Flash column chromatography was performed using a Teledyne ISCO CombiFlash Rf+ 
purification system with RediSep Rf Gold Normal-Phase Silica columns (average particle size: 20 
– 40 µm; average pore size: 60 Å). 
  
Known compounds were characterized by, at minimum, 1H NMR spectroscopy. Novel synthetic 
intermediates and final compounds were characterized by, at minimum, 1H NMR and 13C NMR 
spectroscopy and HRMS. Further NMR experiments were performed as needed to confirm 
structural assignment. 
 
NMR spectra were recorded on Bruker UltraShield 300 MHz and Ascend 400 MHz spectrometers. 
1H and 13C NMR chemical shifts are reported using residual non-deuterated solvent as an internal 
standard – CDCl3: 7.26 (1H), 77.16 (13C) ppm. Multiplicity abbreviations are as follows: s = singlet, 
br s = broad singlet, d = doublet (dd = doublet of doublets, etc.), t = triplet, q = quartet, m = 
multiplet. All NMR data were collected at 25 °C. All deuterated solvents were purchased from 
Cambridge Isotope Laboratories. 
 
High-resolution mass spectra were acquired on an Agilent 1290 Infinity separations module 
coupled to a 6230 time-of-flight (TOF) mass detector operating in ESI+ mode. Masses were 
confirmed using the “Find by Formula” feature in MassHunter Qualitative Analysis vB.06.00. All 
values are averages of three independent measurements. 
 
U-2 OS cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), 1X GlutaMAX, and 1% penicillin/streptomycin (PS) and maintained 
in a 37 °C, 5% CO2 humidified incubator. 
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2. Chemistry Methods 
 
General Synthetic Procedures 
 
Scheme S1. Substrate preparation and overall scheme  
 
 
 
*Thermal rearrangements were performed in CDCl3 so reaction progress could be easily monitored via 1H 
NMR spectroscopy. As seen in Table S1, this transformation proceeds in comparable yields in several 
different solvents; CDCl3 was simply the most convenient. 
 
 
Table S1. Influence of solvent on thermal rearrangement 
 
 
 
Solvent Yield 
CDCl3 70% 
THF 68% 
Ethyl acetate 71% 
Toluene 68% 
 
 
General Procedure A: Tosylation 
To a flame-dried round-bottom flask under an atmosphere of N2 was added tosyl chloride (1.1 
equiv.), DMAP (0.15 equiv.), anhydrous DCM (0.2 M), anhydrous NEt3 (2 equiv.), and the 
corresponding homoallylic alcohol (1 equiv.). The resulting light yellow solution turned cloudy after 
5-10 minutes and was allowed to stir at room temperature for 3 hours. The reaction was quenched 
with H2O and diluted with hexanes. The phases were separated and the organic phase was 
washed twice with saturated aqueous NH4Cl, dried over Na2SO4, and concentrated under reduced 
pressure. The crude yellow oil was purified via flash column chromatography to afford the desired 
tosylate. 
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General Procedure B: Pyrrole alkylation 
To a solution of the corresponding pyrrole (1 equiv.) in anhydrous DMF (0.4 M) was added the 
corresponding tosylate (1.6 equiv.) and cesium carbonate (2.3 equiv.). The reaction mixture was 
stirred at 85 °C for 16 hours, at which point the reaction vessel was allowed to cool to room 
temperature and its contents were partitioned between Et2O and water. The phases were 
separated and the organic phase was washed an additional 3 times with water, dried over 
Na2SO4, and concentrated under reduced pressure. The crude product was purified via flash 
column chromatography to afford the desired alkylated pyrrole. 
 
General Procedure C: Photochemical rearrangement of N-substituted pyrroles 
To a quartz round-bottom flask was added the corresponding pyrrole and acetonitrile (5 mM), and 
the resulting colorless solution was sparged with N2 for 30 minutes. The reaction flask was then 
placed in a Rayonet photochemical reactor outfitted with a cooling fan and eight low pressure 254 
nm (4 W) Hg lamps. The reaction mixture was irradiated until TLC analysis revealed that the 
reaction had gone to completion (usually 3-12 hours). The solvent was then removed under 
reduced pressure and the crude oil was purified via flash column chromatography to afford the 
desired tricyclic aziridine. 
 
General Procedure D: Thermal rearrangement of tricyclic aziridines 
To a 1 dram vial was added the corresponding aziridine and CDCl3 (0.1 M). The vial was tightly 
capped and placed in a heating block raised to 70 °C. The reaction mixture was allowed to stir 
until 1H NMR analysis indicated that the reaction had gone to completion (usually 24-48 hours). 
The solvent was then removed under reduced pressure and the crude oil was either filtered 
through activated charcoal or purified via flash column chromatography to afford the desired 
imine/amine. 
 
 
Compounds 
 
 
 
But-3-en-1-yl 4-methylbenzenesulfonate 
 
General procedure A was followed using but-3-en-1-ol (335 mg, 4.64 mmol) to afford the title 
compound as a colorless oil (1.04 g, 99% yield). 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.2 Hz, 
2H), 7.34 (d, J = 8.2 Hz, 2H), 5.67 (ddt, J = 17.1, 10.4, 6.7 Hz, 1H), 5.11 – 5.07 (m, 1H), 5.06 – 
5.04 (m, 1H), 4.06 (t, J = 6.7 Hz, 2H), 2.45 (s, 3H), 2.40 (qt, J = 6.7, 1.4 Hz, 2H). Characterization 
data consistent with those reported in the literature.1 
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(±) 2-methylbut-3-en-1-yl 4-methylbenzenesulfonate 
 
General procedure A was followed using 2-methylbut-3-en-1-ol (585 mg, 6.79 mmol) to afford the 
title compound as a colorless oil (1.53 g, 94% yield). 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.2 
Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 5.63 (ddd, J = 17.3, 10.4, 7.0 Hz, 1H), 5.08 – 5.01 (m, 2H), 3.92 
(dd, J = 9.4, 6.4 Hz, 1H), 3.84 (dd, J = 9.4, 6.9 Hz, 1H), 2.56 – 2.47 (m, 1H), 2.45 (s, 3H), 1.01 (d, 
J = 6.9 Hz, 3H). Characterization data consistent with those reported in the literature.2 
 
 
 
 
3-methylbut-3-en-1-yl 4-methylbenzenesulfonate  
 
General procedure A was followed using 3-methylbut-3-en-1-ol (597 mg, 6.79 mmol) to afford the 
title compound as a colorless oil (1.52 g, 91% yield). 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.1 
Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 4.77 (br s, 1H), 4.66 (br s, 1H), 4.11 (t, J = 6.9 Hz, 2H), 2.43 (s, 
3H), 2.33 (t, J = 6.9 Hz, 2H), 1.64 (s, 3H). Characterization data consistent with those reported in 
the literature.3  
 
 
 
 
1-(1-(but-3-en-1-yl)-1H-pyrrol-2-yl)ethan-1-one (1a) 
 
General procedure B was followed using 2-acetyl-1H-pyrrole (678 mg, 6.21 mmol) and but-3-en-
1-yl 4-methylbenzenesulfonate (2.25 g, 9.94 mmol) to afford the title compound as a colorless oil 
(950 mg, 94% yield). 1H NMR (400 MHz, CDCl3) δ 6.95 (dd, J = 4.1, 1.7 Hz, 1H), 6.84 – 6.80 (m, 
1H), 6.10 (dd, J = 4.1, 2.6 Hz, 1H), 5.74 (ddt, J = 17.0, 10.2, 6.8 Hz, 1H), 5.06 – 4.98 (m, 2H), 
4.36 (t, J = 7.1 Hz, 2H), 2.50 – 2.43 (m, 2H), 2.42 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 188.2, 
134.7, 130.3, 130.0, 120.4, 117.2, 107.9, 49.3, 35.8, 27.3. HRMS (ESI+) C10H13NO – calculated: 
163.0997, found: 163.0999. Characterization data consistent with those reported in the literature.4  
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(±) 1-(1-(2-methylbut-3-en-1-yl)-1H-pyrrol-2-yl)ethan-1-one (2a) 
 
General procedure B was followed using 2-acetyl-1H-pyrrole (227 mg, 2.08 mmol) and 2-
methylbut-3-en-1-yl 4-methylbenzenesulfonate (800 mg, 3.33 mmol) to afford the title compound 
as a colorless oil (234 mg, 64% yield). 1H NMR (400 MHz, CDCl3) δ 6.95 (dd, J = 4.1, 1.7 Hz, 1H), 
6.82 – 6.76 (m, 1H), 6.08 (dd, J = 4.1, 2.5 Hz, 1H), 5.69 (ddd, J = 16.9, 10.6, 7.4 Hz, 1H), 4.97 – 
4.88 (m, 2H), 4.23 (dd, J = 13.1, 7.0 Hz, 1H), 4.17 (dd, J = 13.1, 7.6 Hz, 1H), 2.69 – 2.57 (m, 1H), 
2.42 (s, 3H), 0.97 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 188.4, 140.8, 131.1, 130.2, 
120.5, 114.9, 107.6, 55.3, 39.4, 27.4, 17.1. HRMS (ESI+) C11H15NO – calculated: 177.1154, 
found: 177.1155. 
 
 
 
 
1-(1-(3-methylbut-3-en-1-yl)-1H-pyrrol-2-yl)ethan-1-one (3a) 
 
General procedure B was followed using 2-acetyl-1H-pyrrole (97 mg, 0.892 mmol) and 3-
methylbut-3-en-1-yl 4-methylbenzenesulfonate (343 mg, 1.43 mmol) to afford the title compound 
as a colorless oil (145 mg, 92% yield). 1H NMR (400 MHz, CDCl3) δ 6.93 (dd, J = 4.1, 1.7 Hz, 1H), 
6.84 – 6.79 (m, 1H), 6.09 (dd, J = 4.1, 2.5 Hz, 1H), 4.77 – 4.74 (m, 1H), 4.68 – 4.61 (m, 1H), 4.44 
– 4.35 (m, 2H), 2.43 – 2.38 (m, 5H), 1.74 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 188.1, 142.4, 
130.2, 130.0, 120.3, 112.3, 107.9, 48.6, 39.6, 27.3, 22.5. HRMS (ESI+) C11H15NO – calculated: 
177.1154, found: 177.1153. 
 
 
 
 
1-(but-3-en-1-yl)-1H-pyrrole-2-carbonitrile (4a) 
 
General procedure B was followed using 1H-pyrrole-2-carbonitrile (147 mg, 1.89 mmol) and but-
3-en-1-yl 4-methylbenzenesulfonate (684 mg, 3.02 mmol) to afford the title compound as a 
colorless oil (249 mg, 90% yield). 1H NMR (400 MHz, CDCl3) δ 6.83 (dd, J = 2.7, 1.6 Hz, 1H), 
6.76 (dd, J = 4.0, 1.6 Hz, 1H), 6.15 (dd, J = 4.0, 2.7 Hz, 1H), 5.73 (ddt, J = 17.3, 10.6, 6.9 Hz, 
1H), 5.10 – 5.03 (m, 2H), 4.09 (t, J = 7.0 Hz, 2H), 2.59 – 2.52 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 133.4, 126.5, 120.1, 118.4, 114.0, 109.4, 103.6, 48.5, 35.5. HRMS (ESI+) C9H10N2 – 
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calculated: 146.0844, found: 146.0849. Characterization data consistent with those reported in 
the literature.4  
 
 
 
 
(±) 1-(2-methylbut-3-en-1-yl)-1H-pyrrole-2-carbonitrile (5a) 
 
General procedure B was followed using 1H-pyrrole-2-carbonitrile (128 mg, 1.40 mmol) and 2-
methylbut-3-en-1-yl 4-methylbenzenesulfonate (540 mg, 2.24 mmol) to afford the title compound 
as a colorless oil (186 mg, 83% yield). 1H NMR (400 MHz, CDCl3) δ 6.80 (dd, J = 2.7, 1.6 Hz, 1H), 
6.75 (dd, J = 4.0, 1.6 Hz, 1H), 6.14 (dd, J = 4.0, 2.7 Hz, 1H), 5.68 (ddd, J = 17.1, 10.4, 7.5 Hz, 
1H), 5.04 – 4.95 (m, 2H), 3.98 – 3.88 (m, 2H), 2.75 – 2.62 (m, 1H), 1.02 (d, J = 6.8 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 139.5, 127.0, 119.9, 116.1, 114.1, 109.3, 104.0, 54.4, 39.8, 17.2. HRMS 
(ESI+) C10H12N2 – calculated: 160.1000, found: 160.1002. 
 
 
 
 
1-(3-methylbut-3-en-1-yl)-1H-pyrrole-2-carbonitrile (6a) 
 
General procedure B was followed using 1H-pyrrole-2-carbonitrile (164 mg, 1.78 mmol) and 3-
methylbut-3-en-1-yl 4-methylbenzenesulfonate (684 mg, 2.85 mmol) to afford the title compound 
as a colorless oil (276 mg, 97% yield). 1H NMR (400 MHz, CDCl3) δ 6.83 (dd, J = 2.6, 1.6 Hz, 1H), 
6.76 (dd, J = 4.0, 1.6 Hz, 1H), 6.14 (dd, J = 4.0, 2.6 Hz, 1H), 4.84 – 4.78 (m, 1H), 4.69 – 4.64 (m, 
1H), 4.14 (t, J = 7.3 Hz, 2H), 2.50 (t, J = 7.3 Hz, 2H), 1.76 (s, 3H). HRMS (ESI+) C10H12N2 – 
calculated: 160.1000, found: 160.0999. Characterization data consistent with those reported in 
the literature.5  
 
 
 
 
Ethyl 4-acetyl-1-(but-3-en-1-yl)-3,5-dimethyl-1H-pyrrole-2-carboxylate (7a) 
 
General procedure B was followed using ethyl 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carboxylate 
(396 mg, 1.89 mmol) and but-3-en-1-yl 4-methylbenzenesulfonate (684 mg, 3.02 mmol) to afford 
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the title compound as a colorless oil (474 mg, 95% yield). 1H NMR (400 MHz, CDCl3) δ 5.73 (ddt, 
J = 17.1, 10.2, 6.9 Hz, 1H), 5.08 – 4.99 (m, 2H), 4.32 – 4.23 (m, 4H), 2.48 (s, 3H), 2.43 (s, 3H), 
2.42 – 2.34 (m, 5H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 196.1, 161.7, 139.3, 
134.0, 129.1, 123.3, 119.5, 117.2, 59.9, 44.5, 34.9, 31.6, 14.3, 13.3, 12.1. HRMS (ESI+) 
C15H21NO3 – calculated: 263.1521, found: 263.1527. Characterization data consistent with those 
reported in the literature.4 
 
 
 
 
(±) Ethyl 4-acetyl-3,5-dimethyl-1-(2-methylbut-3-en-1-yl)-1H-pyrrole-2-carboxylate (8a) 
 
General procedure B was followed using ethyl 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carboxylate 
(184 mg, 0.881 mmol) and 2-methylbut-3-en-1-yl 4-methylbenzenesulfonate (340 mg, 1.41 mmol) 
to afford the title compound as a colorless oil (214 mg, 88% yield). 1H NMR (400 MHz, CDCl3) δ 
5.62 (ddd, J = 17.4, 10.4, 7.4 Hz, 1H), 4.94 – 4.85 (m, 2H), 4.29 (q, J = 7.1 Hz, 2H), 4.19 (br s, 
2H), 2.57 – 2.48 (m, 4H), 2.45 – 2.39 (m, 6H), 1.35 (t, J = 7.1 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 196.6, 162.2, 140.2, 140.0, 129.4, 123.5, 120.1, 115.3, 60.1, 50.1, 
39.5, 32.0, 17.0, 14.5, 13.7, 12.9. HRMS (ESI+) C16H23NO3 – calculated: 277.1678, found: 
277.1683. 
 
 
 
 
Ethyl 4-acetyl-3,5-dimethyl-1-(3-methylbut-3-en-1-yl)-1H-pyrrole-2-carboxylate (9a) 
 
General procedure B was followed using ethyl 4-acetyl-3,5-dimethyl-1H-pyrrole-2-carboxylate 
(373 mg, 1.78 mmol) and 3-methylbut-3-en-1-yl 4-methylbenzenesulfonate (684 mg, 3.02 mmol) 
to afford the title compound as a colorless oil (483 mg, 98% yield). 1H NMR (400 MHz, CDCl3) δ 
4.80 (s, 1H), 4.73 – 4.70 (m, 1H), 4.38 – 4.27 (m, 4H), 2.51 (s, 3H), 2.47 (s, 3H), 2.44 (s, 3H), 
2.36 – 2.29 (m, 2H), 1.78 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 196.5, 
161.9, 142.2, 139.5, 129.2, 123.6, 119.8, 112.2, 60.1, 44.3, 38.7, 31.9, 22.7, 14.5, 13.6, 12.1. 
HRMS (ESI+) C16H23NO3 – calculated: 277.1678, found: 277.1685. 
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1-(1-(but-3-en-1-yl)-1H-pyrrol-2-yl)-2,2,2-trichloroethan-1-one 
 
To a flame-dried round-bottom flask under an atmosphere of N2 was added 2,2,2-trichloro-1-(1H-
pyrrol-2-yl)ethanone (300 mg, 1 equiv.), triphenylphosphine (0.926 g, 2.5 equiv.), anhydrous THF 
(8 ml, 0.16 M), and but-3-en-1-ol (305 mg, 3 equiv.). The resulting colorless solution was cooled 
to 0 °C. Once cool, DIAD (0.686 ml, 2.5 equiv.) was added dropwise via syringe over the course 
of 30 minutes to afford a yellow solution. The ice bath was allowed to melt slowly and the reaction 
mixture stirred for 24 hours. Solvent was removed under reduced pressure and the resulting 
yellow oil was partitioned between 25 mL Et2O and 2 mL H2O. The phases were separated and 
the organic phase was washed with an additional 2 x 2 mL H2O, dried over Na2SO4, and 
concentrated under reduced pressure. The crude reaction product was purified via flash column 
chromatography (ISCO, Silica 24 g, 0-10% EtOAc in hexanes) to afford the title compound as a 
colorless oil (230 mg, 61% yield). 1H NMR (400 MHz, CDCl3) δ 7.54 (dd, J = 4.4, 1.6 Hz, 1H), 7.00 
(dd, J = 2.4, 1.6 Hz, 1H), 6.22 (dd, J = 4.4, 2.4 Hz, 1H), 5.76 (ddt, J = 16.9, 9.8, 7.0 Hz, 1H), 5.08 
– 5.02 (m, 2H), 4.39 (t, J = 7.1 Hz, 2H), 2.50 (qt, J = 7.0, 1.3 Hz, 2H). Characterization data 
consistent with those reported in the literature.4 
 
 
 
 
1-(but-3-en-1-yl)-N-(adamantan-1-ylmethyl)-1H-pyrrole-2-carboxamide (10a) 
 
To a solution of 1-(1-(but-3-en-1-yl)-1H-pyrrol-2-yl)-2,2,2-trichloroethan-1-one (140 mg, 0.525 
mmol) in acetonitrile (1.0 mL, 0.42 M) was added triethylamine (0.110 mL, 0.788 mmol, 1.5 equiv.) 
and adamantan-1-ylmethanamine (0.140 mL, 0.788 mmol, 1.5 equiv.). The resulting colorless 
solution was allowed to stir at 50 °C for 5 hours, during which time the reaction mixture turned 
bright orange. The reaction vial was then allowed to cool to room temperature and its contents 
were diluted with 75 mL hexanes, washed with 2 x 5 mL saturated aqueous NH4Cl and 5 mL H2O, 
dried over Na2SO4, and concentrated under reduced pressure. The crude light yellow oil was 
purified via flash column chromatography (ISCO, Silica 12g, 0-10% EtOAc in hexanes) to afford 
the title compound as a colorless oil (160 mg, 97% yield). 1H NMR (400 MHz, CDCl3) δ 6.75 (dd, 
J = 2.5, 1.7 Hz, 1H), 6.52 (dd, J = 3.9, 1.7 Hz, 1H), 6.07 (dd, J = 3.9, 2.5 Hz, 1H), 5.94 (br s, 1H), 
5.76 (ddt, J = 17.2, 10.2, 6.9 Hz, 1H), 5.06 – 4.97 (m, 2H), 4.39 (t, J = 7.1 Hz, 2H), 3.07 (d, J = 
6.5 Hz, 2H), 2.55 – 2.48 (m, 2H), 2.00 – 1.96 (m, 3H), 1.74 – 1.69 (m, 3H), 1.65 – 1.60 (m, 3H), 
1.54 (d, J = 2.9 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 162.1, 135.1, 126.8, 125.6, 117.0, 111.3, 
107.1, 50.6, 48.5, 40.4, 37.1, 36.3, 34.2, 28.4. HRMS (ESI+) C20H28N2O – calculated: 312.2202, 
found: 312.2208. 
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(±) 1-((31R,3aS,6aS)-1,3a,6,6a-tetrahydroazirino[2,3,1-hi]indol-31(2H)-yl)ethan-1-one (1b) 
 
General procedure C was followed using pyrrole 1a (230 mg, 1.40 mmol) to afford the title 
compound as a yellow oil (149 mg, 65% yield). 1H NMR (400 MHz, CDCl3) δ 6.18 (dddd, J = 10.0, 
6.1, 2.0, 0.9 Hz, 1H), 5.74 (dddd, J = 10.0, 4.1, 3.3, 0.9 Hz, 1H), 3.22 (ddd, J = 9.7, 4.3, 2.0 Hz, 
1H), 3.16 – 3.06 (m, 1H), 2.80 (d, J = 3.8 Hz, 1H), 2.52 (ddd, J = 11.4, 10.0, 8.0 Hz, 1H), 2.46 – 
2.33 (m, 1H), 2.25 – 2.18 (m, 1H), 2.03 (s, 3H), 1.93 – 1.85 (m, 1H), 1.50 – 1.42 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 208.5, 135.7, 120.1, 59.5, 49.9, 44.0, 41.1, 31.9, 29.8, 24.3. HRMS (ESI+) 
C10H13NO – calculated: 163.0997, found: 163.0998. Characterization data consistent with those 
reported in the literature.4 
 
 
 
 
(±) 1-((31R,3aS,6aS)-6a-methyl-1,3a,6,6a-tetrahydroazirino[2,3,1-hi]indol-31(2H)-yl)ethan-1-
one (2b) 
 
General procedure C was followed using pyrrole 2a (158 mg, 0.891 mmol) to afford the title 
compound as a light yellow oil (81 mg, 51% yield, d.r. = 6:1). 1H NMR (400 MHz, CDCl3) δ 6.21 
(dddd, J = 10.0, 6.0, 2.0, 0.8 Hz, 1H), 5.74 (dddd, J = 10.0, 4.1, 3.2, 1.1 Hz, 1H), 2.83 – 2.78 (m, 
2H), 2.76 – 2.71 (m, 2H), 2.29 – 2.20 (m, 1H), 2.08 (s, 3H), 2.01 – 1.92 (m, 2H), 0.99 (d, J = 7.2 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 208.6, 135.6, 119.7, 58.5, 56.8, 50.3, 43.6, 40.1, 29.2, 
24.1, 22.7. HRMS (ESI+) C11H15NO – calculated: 177.1154, found: 177.1153. 
 
 
 
 
(±) 1-((31R,3aS,6aS)-6a-methyl-1,3a,6,6a-tetrahydroazirino[2,3,1-hi]indol-31(2H)-yl)ethan-1-
one (3b) 
 
General procedure C was followed using pyrrole 3a (131 mg, 0.739 mmol) to afford the title 
compound as a light yellow oil (63 mg, 48% yield). 1H NMR (300 MHz, CDCl3) δ 6.19 (ddd, J = 
10.0, 6.2, 2.0 Hz, 1H), 5.78 (dddd, J = 10.0, 4.0, 3.2, 1.0 Hz, 1H), 3.15 (td, J = 11.6, 3.2 Hz, 1H), 
2.49 (dt, J = 12.1, 9.0 Hz, 1H), 2.41 (d, J = 3.7 Hz, 1H), 2.33 – 2.23 (m, 1H), 2.13 – 2.02 (m, 4H), 
1.88 (dd, J = 17.2, 6.1 Hz, 1H), 1.70 – 1.59 (m, 1H), 1.26 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
208.5, 136.1, 120.8, 59.7, 48.6, 48.2, 42.1, 42.0, 38.5, 27.6, 26.9. HRMS (ESI+) C11H15NO – 
calculated: 177.1154, found: 177.1154. 
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(±) (31R,3aS,6aS)-1,3a,6,6a-tetrahydroazirino[2,3,1-hi]indole-31(2H)-carbonitrile (4b) 
 
General procedure C was followed using pyrrole 4a (241 mg, 1.65 mmol) to afford the title 
compound as an orange oily solid (67 mg, 28% yield). 1H NMR (400 MHz, CDCl3) δ 6.25 – 6.16 
(m, 1H), 5.77 (dtd, J = 10.2, 3.6, 1.0 Hz, 1H), 3.21 (td, J = 11.1, 2.4 Hz, 1H), 2.97 – 2.91 (m, 1H), 
2.85 (d, J = 3.7 Hz, 1H), 2.74 – 2.61 (m, 1H), 2.47 (ddd, J = 11.7, 10.0, 7.8 Hz, 1H), 2.41 – 2.33 
(m, 1H), 1.98 – 1.90 (m, 1H), 1.62 – 1.54 (m, 1H). HRMS (ESI+) C9H10N2 – calculated: 146.0844, 
found: 146.0844. Characterization data consistent with those reported in the literature.4 
 
 
 
(±) (1S,31R,3aS,6aS)-1-methyl-1,3a,6,6a-tetrahydroazirino[2,3,1-hi]indole-31(2H)-
carbonitrile (5b) 
General procedure C was followed using pyrrole 5a (234 mg, 1.46 mmol) to afford the title 
compound as a yellow-orange oil (98 mg, 42% yield, d.r. = 4:1). 1H NMR (400 MHz, CDCl3) δ 6.22 
(dddd, J = 10.2, 6.1, 2.2, 0.8 Hz, 1H), 5.77 (dddd, J = 10.2, 4.1, 3.3, 1.1 Hz, 1H), 2.89 – 2.77 (m, 
2H), 2.68 (dd, J = 12.0, 6.8 Hz, 1H), 2.50 (d, J = 5.0 Hz, 1H), 2.43 – 2.33 (m, 1H), 2.13 – 1.95 (m, 
2H), 1.22 (d, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 134.6, 121.4, 119.2, 56.6, 51.9, 45.8, 
42.8, 37.6, 28.4, 22.9. HRMS (ESI+) C10H12N2 – calculated: 160.1000, found: 160.1000. 
 
 
 
 
(±) (31R,3aS,6aS)-1,3a,6,6a-tetrahydroazirino[2,3,1-hi]indole-31(2H)-carbonitrile (6b) 
 
General procedure C was followed using pyrrole 6a (200 mg, 1.25 mmol) to afford the title 
compound as a light yellow oil (58 mg, 29% yield). 1H NMR (400 MHz, CDCl3) δ 6.22 (ddd, J = 
10.1, 6.2, 2.1 Hz, 1H), 5.80 (dtd, J = 10.1, 3.4, 1.0 Hz, 1H), 3.21 (td, J = 11.5, 2.7 Hz, 1H), 2.87 
(d, J = 3.6 Hz, 1H), 2.48 (ddd, J = 11.9, 9.8, 8.3 Hz, 1H), 2.27 (dddd, J = 12.7, 11.1, 9.8, 1.5 Hz, 
1H), 2.21 – 2.14 (m, 1H), 1.98 (dd, J = 17.6, 6.2 Hz, 1H), 1.81 – 1.73 (m, 1H), 1.46 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 135.3, 119.7, 119.4, 49.4, 48.9, 44.2, 43.3, 41.5, 37.2, 27.7. HRMS 
(ESI+) C10H12N2 – calculated: 160.1000, found: 160.1000. 
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(±) Ethyl (31R,3aS,6aS)-4-acetyl-3a,5-dimethyl-1,3a,6,6a-tetrahydroazirino[2,3,1-hi]indole-
31(2H)-carboxylate (7b) 
 
General procedure C was followed using pyrrole 7a (100 mg, 0.380 mmol) to afford the title 
compound as an orange oil (75 mg, 75% yield). 1H NMR (400 MHz, CDCl3) δ 4.31 – 4.16 (m, 2H), 
3.46 – 3.34 (m, 1H), 3.03 – 2.95 (m, 1H), 2.77 – 2.64 (m, 2H), 2.55 – 2.41 (m, 1H), 2.27 (s, 3H), 
1.94 (s, 3H), 1.90 (dd, J = 17.1, 2.4 Hz, 1H), 1.43 (ddt, J = 13.5, 8.6, 2.4 Hz, 1H), 1.28 (t, J = 7.2 
Hz, 3H), 1.24 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 203.3, 171.2, 144.1, 132.4, 61.3, 59.7, 51.6, 
47.8, 38.8, 37.6, 36.9, 30.0, 21.8, 18.9, 14.5. HRMS (ESI+) C15H21NO3 – calculated: 263.1521, 
found: 263.1526. Characterization data consistent with those reported in the literature.4 
 
 
 
 
(±) Ethyl (1S,31R,3aS,6aS)-4-acetyl-1,3a,5-trimethyl-1,3a,6,6a-tetrahydroazirino[2,3,1-
hi]indole-31(2H)-carboxylate (8b) 
 
General procedure C was followed using pyrrole 8a (177 mg, 0.638 mmol) to afford the title 
compound as a light yellow oil (67 mg, 38% yield, d.r. > 10:1). 1H NMR (400 MHz, CDCl3) δ 4.22 
(q, J = 7.1 Hz, 2H), 2.95 (dd, J = 12.5, 2.4 Hz, 1H), 2.84 (dd, J = 12.5, 7.2 Hz, 1H), 2.62 (ddd, J = 
17.3, 4.8, 1.4 Hz, 1H), 2.49 – 2.43 (m, 1H), 2.21 (s, 3H), 1.95 – 1.83 (m, 5H), 1.25 (t, J = 7.1 Hz, 
3H), 1.19 (s, 3H), 1.05 (d, J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 203.4, 171.4, 143.7, 
132.2, 61.3, 58.9, 58.7, 48.4, 47.3, 45.6, 36.8, 29.9, 23.0, 21.4, 18.9, 14.4. HRMS (ESI+) 
C16H23NO3 – calculated: 277.1678, found: 277.1683. 
 
 
 
(±) Ethyl (31R,3aS,6aS)-4-acetyl-3a,5,6a-trimethyl-1,3a,6,6a-tetrahydroazirino[2,3,1-
hi]indole-31(2H)-carboxylate (9b) 
General procedure C was followed using pyrrole 9a (151 mg, 0.544 mmol) to afford the title 
compound as a light yellow oil (62 mg, 41% yield). 1H NMR (400 MHz, CDCl3) δ 4.31 – 4.16 (m, 
2H), 3.39 (ddd, J = 12.7, 11.2, 3.5 Hz, 1H), 2.65 (dt, J = 12.7, 8.9 Hz, 1H), 2.58 (d, J = 16.9 Hz, 
1H), 2.27 (s, 3H), 2.19 – 2.09 (m, 1H), 1.93 (d, J = 1.2 Hz, 3H), 1.82 (d, J = 16.9 Hz, 1H), 1.69 – 
1.59 (m, 1H), 1.28 (t, J = 7.2 Hz, 3H), 1.26 (s, 3H), 1.16 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
S14 
 
203.4, 169.8, 145.2, 132.4, 62.8, 61.0, 50.2, 47.1, 46.8, 45.9, 42.7, 30.2, 26.0, 21.7, 20.3, 14.5. 
HRMS (ESI+) C16H23NO3 – calculated: 277.1678, found: 277.1682. 
 
 
 
 
(±) (31R,3aS,6aS)-N-(((3S)-adamantan-1-yl)methyl)-1,3a,6,6a-tetrahydroazirino[2,3,1-
hi]indole-31(2H)-carboxamide (10b) 
 
General procedure C was followed using pyrrole 10a (156 mg, 0.499 mmol) to afford the title 
compound as a colorless oily solid (78 mg, 50% yield). 1H NMR (400 MHz, CDCl3) δ 6.68 (br s, 
1H), 6.23 (ddd, J = 10.1, 6.1, 1.9 Hz, 1H), 5.73 (dt, J = 10.1, 3.4 Hz, 1H), 3.14 – 3.03 (m, 3H), 
2.68 (dd, J = 13.4, 5.3 Hz, 1H), 2.57 – 2.39 (m, 4H), 1.97 – 1.91 (m, 4H), 1.68 (d, J = 12.3 Hz, 
3H), 1.59 (d, J = 12.3 Hz, 3H), 1.47 – 1.38 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 172.6, 135.8, 
120.0, 53.4, 50.4, 49.2, 44.8, 41.2, 40.4, 37.1, 34.2, 33.9, 30.2, 28.4. HRMS (ESI+) C20H28N2O – 
calculated: 312.2202, found: 312.2207. 
 
 
 
 
(±) 1-((3aS,7aR)-3,3a,4,5-tetrahydro-7aH-indol-7a-yl)ethan-1-one (1c) 
 
General procedure D was followed using aziridine 1b (47 mg, 0.288 mmol) to afford the title 
compound as a colorless oil (33 mg, 70% yield). 1H NMR (400 MHz, CDCl3) δ 7.60 (s, 1H), 6.03 
(ddd, J = 10.1, 4.4, 3.4 Hz, 1H), 5.95 (dt, J = 10.1, 1.9 Hz, 1H), 2.77 – 2.64 (m, 2H), 2.36 (ddd, J 
= 16.7, 4.5, 1.3 Hz, 1H), 2.27 (s, 3H), 2.07 – 1.94 (m, 2H), 1.88 – 1.79 (m, 1H), 1.40 – 1.30 (m, 
1H). 13C NMR (101 MHz, CDCl3) δ 207.6, 167.5, 131.9, 125.9, 86.7, 42.6, 35.1, 26.4, 24.9, 22.0. 
HRMS (ESI+) C10H13NO – calculated: 163.0997, found: 163.0997. 
 
 
 
 
(±) 1-((3S,3aS,7aS)-3-methyl-3,3a,4,5-tetrahydro-7aH-indol-7a-yl)ethan-1-one (2c) 
 
General procedure D was followed using aziridine 2b (90 mg, 0.508 mmol) to afford the title 
compound as a colorless oil (54 mg, 60% yield). 1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 5.94 
(dt, J = 10.2, 3.6 Hz, 1H), 5.82 – 5.77 (m, 1H), 2.76 – 2.67 (m, 1H), 2.35 (s, 3H), 2.25 (dt, J = 9.3, 
4.8 Hz, 1H), 2.07 – 1.92 (m, 3H), 1.71 – 1.63 (m, 1H), 1.15 (d, J = 7.2 Hz, 3H). 13C NMR (101 
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MHz, CDCl3) δ 208.9, 172.4, 130.8, 125.7, 86.5, 47.3, 43.7, 26.5, 21.6, 21.1, 15.4. HRMS (ESI+) 
C11H15NO – calculated: 177.1154, found: 177.1156. 
 
 
 
 
(±) (3aS,7aS)-3a-methyl-3a,4,5,7a-tetrahydro-3H-indole (3c) 
 
General procedure D was followed using aziridine 3b (95 mg, 0.536 mmol) to afford the title 
compound as a colorless oil (57 mg, 60% yield). 1H NMR (400 MHz, CDCl3) δ 7.68 (s, 1H), 5.90 
(dt, J = 10.1, 3.7 Hz, 1H), 5.58 (dt, J = 10.1, 2.2 Hz, 1H), 2.62 (d, J = 17.5 Hz, 1H), 2.28 (s, 3H), 
2.23 (dd, J = 17.2, 1.3 Hz, 1H), 2.14 – 2.09 (m, 2H), 1.88 (dt, J = 13.7, 7.8 Hz, 1H), 1.64 (dt, J = 
13.8, 4.8 Hz, 1H), 0.93 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 210.6, 168.2, 128.6, 126.6, 86.6, 
48.1, 42.5, 30.1, 29.7, 24.3, 21.6. HRMS (ESI+) C11H15NO – calculated: 177.1154, found: 
177.1154. 
 
 
 
 
(±) (3aS,7aR)-3,3a,4,5-tetrahydro-7aH-indole-7a-carbonitrile (4c) 
 
General procedure D was followed using aziridine 4b (50 mg, 0.342 mmol) to afford the title 
compound as a colorless oil (19 mg, 38% yield). 1H NMR (400 MHz, CDCl3) δ 7.72 (s, 1H), 6.09 
(dt, J = 10.0, 4.0 Hz, 1H), 5.97 (dt, J = 10.0, 2.1 Hz, 1H), 2.94 (ddd, J = 17.7, 8.2, 1.1 Hz, 1H), 
2.81 (tt, J = 8.4, 4.9 Hz, 1H), 2.52 (ddd, J = 17.7, 4.9, 1.2 Hz, 1H), 2.09 – 2.03 (m, 2H), 1.88 (ddt, 
J = 13.7, 6.3, 5.0 Hz, 1H), 1.40 (dddd, J = 14.0, 8.7, 7.0, 5.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) 
δ 170.4, 132.5, 123.7, 120.6, 69.8, 42.5, 40.2, 23.4, 21.5. HRMS (ESI+) C9H10N2 – calculated: 
146.0844, found: 146.0843. 
 
 
 
 
(±) (3S,3aS,7aS)-3-methyl-3,3a,4,5-tetrahydro-7aH-indole-7a-carbonitrile (5c) 
 
General procedure D was followed using aziridine 5b (18 mg, 0.112 mmol) to afford the title 
compound as a light yellow oil (10 mg, 55% yield). 1H NMR (400 MHz, CDCl3) δ 7.53 (s, 1H), 6.00 
(dt, J = 10.0, 3.9 Hz, 1H), 5.81 (dt, J = 10.0, 2.0 Hz, 1H), 2.84 – 2.74 (m, 1H), 2.45 – 2.37 (m, 1H), 
2.10 – 1.98 (m, 3H), 1.75 – 1.65 (m, 1H), 1.26 (d, J = 7.3 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
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174.8, 131.4, 123.8, 121.3, 69.8, 48.4, 47.3, 20.7, 20.7, 15.1. HRMS (ESI+) C10H12N2 – calculated: 
160.1000, found 160.1001. 
 
 
 
 
(±) (3aS,7aS)-3a-methyl-3,3a,4,5-tetrahydro-7aH-indole-7a-carbonitrile (6c) 
 
General procedure D was followed using aziridine 6b (21 mg, 0.131 mmol) to afford the title 
compound as a colorless oil (14 mg, 67% yield). 1H NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 5.99 
(dt, J = 10.0, 3.8 Hz, 1H), 5.85 (dt, J = 10.0, 2.1 Hz, 1H), 2.64 (dd, J = 17.6, 1.1 Hz, 1H), 2.48 (dd, 
J = 17.6, 1.3 Hz, 1H), 2.14 – 2.06 (m, 2H), 1.73 – 1.62 (m, 2H), 1.33 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.6, 130.8, 124.3, 118.8, 74.4, 48.3, 42.3, 29.6, 24.8, 21.3. HRMS (ESI+) C10H12N2 – 
calculated: 160.1000, found 160.1001. 
 
 
 
 
(±) Ethyl (3aS,7aR)-6-acetyl-7-methyl-5-methylene-1,2,3,3a,4,5-hexahydro-7aH-indole-7a-
carboxylate (7c) 
 
General procedure D was followed using aziridine 7b (24 mg, 0.0911 mmol) to afford the title 
compound as a colorless oil (18 mg, 75% yield). 1H NMR (400 MHz, CDCl3) δ 4.95 (s, 1H), 4.72 
(s, 1H), 4.21 (q, J = 7.1 Hz, 2H), 3.06 (dt, J = 10.1, 7.6 Hz, 1H), 2.90 (ddd, J = 10.1, 8.0, 4.8 Hz, 
1H), 2.74 (ddt, J = 14.1, 4.6, 2.0 Hz, 1H), 2.64 (br s, 1H), 2.44 – 2.33 (m, 2H), 2.31 (s, 3H), 1.88 
(dtd, J = 12.6, 7.6, 4.8 Hz, 1H), 1.67 – 1.59 (m, 4H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 206.5, 175.0, 139.7, 137.3, 132.0, 112.5, 70.1, 61.8, 44.7, 42.6, 33.0, 31.1, 30.4, 15.6, 
14.4. HRMS (ESI+) C15H21NO3 – calculated: 263.1521, found 263.1526. 
 
 
 
 
(±) Ethyl (3S,3aS,7aR)-6-acetyl-3,7-dimethyl-5-methylene-1,2,3,3a,4,5-hexahydro-7aH-
indole-7a-carboxylate (8c) 
 
General procedure D was followed using aziridine 8b (50 mg, 0.180 mmol) to afford the title 
compound as a light yellow oil (22 mg, 44% yield). 1H NMR (400 MHz, CDCl3) δ 4.92 (d, J = 2.1 
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Hz, 1H), 4.69 (d, J = 2.1 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.03 (dd, J = 9.4, 6.9 Hz, 1H), 2.80 
(ddt, J = 14.6, 5.0, 2.3 Hz, 1H), 2.63 (t, J = 9.4 Hz, 1H), 2.54 (br s, 1H), 2.36 (dd, J = 14.6, 2.8 Hz, 
1H), 2.30 (s, 3H), 1.98 – 1.86 (m, 1H), 1.77 (ddd, J = 10.4, 5.0, 2.8 Hz, 1H), 1.59 (s, 3H), 1.25 (t, 
J = 7.1 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 206.5, 175.1, 138.6, 136.9, 
132.8, 112.2, 70.1, 61.8, 53.2, 49.8, 36.6, 31.1, 31.0, 16.2, 15.3, 14.4. HRMS (ESI+) C16H23NO3 
– calculated: 277.1678, found 277.1682. 
 
 
 
 
(±) Ethyl (3aS,7aR)-6-acetyl-3a,7-dimethyl-5-methylene-1,2,3,3a,4,5-hexahydro-7aH-indole-
7a-carboxylate (9c) 
 
General procedure D was followed using aziridine 9b (30 mg, 0.108 mmol) to afford the title 
compound as a colorless oil (17 mg, 57% yield). 1H NMR (400 MHz, CDCl3) δ 4.93 (d, J = 2.1 Hz, 
1H), 4.71 (d, J = 2.1 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 3.10 (dt, J = 10.3, 8.3 Hz, 1H), 2.81 (ddd, 
J = 10.3, 9.0, 3.5 Hz, 1H), 2.70 (dt, J = 14.4, 2.2 Hz, 1H), 2.47 (br s, 1H), 2.34 – 2.28 (m, 4H), 
1.89 (dt, J = 12.6, 9.0 Hz, 1H), 1.60 (s, 3H), 1.46 (ddd, J = 12.6, 8.0, 3.5 Hz, 1H), 1.27 (t, J = 7.1 
Hz, 3H), 0.94 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 206.8, 173.1, 139.1, 137.8, 133.3, 112.3, 
74.0, 61.6, 44.0, 42.8, 40.1, 36.7, 31.1, 24.8, 15.6, 14.4. HRMS (ESI+) C16H23NO3 – calculated: 
277.1678, found 277.1682. 
 
 
 
 
(±) (3aS,7aR)-N-(((3R,5R,7R)-adamantan-1-yl)methyl)-3,3a,4,5-tetrahydro-7aH-indole-7a-
carboxamide (10c) 
 
General procedure D was followed using aziridine 10b (35 mg, 0.112 mmol) to afford the title 
compound as a colorless oil (29 mg, 83% yield). 1H NMR (400 MHz, CDCl3) δ 7.62 (s, 1H), 6.72 
(br s, 1H), 5.98 (dt, J = 10.0, 4.0 Hz, 1H), 5.74 (dt, J = 10.0, 2.1 Hz, 1H), 3.01 (dd, J = 13.4, 6.9 
Hz, 1H), 2.83 (dd, J = 13.4, 6.1 Hz, 1H), 2.75 – 2.63 (m, 2H), 2.48 – 2.38 (m, 1H), 2.22 – 2.13 (m, 
1H), 2.09 – 2.01 (m, 2H), 1.95 (s, 3H), 1.69 (d, J = 12.6 Hz, 3H), 1.60 (d, J = 12.6 Hz, 3H), 1.53 
– 1.44 (m, 7H). 13C NMR (101 MHz, CDCl3) δ 174.3, 168.0, 131.0, 127.1, 80.7, 50.8, 41.9, 40.4, 
37.3, 37.1, 34.0, 28.3, 24.0, 21.0. HRMS (ESI+) C20H28N2O – calculated: 312.2202, found 
312.2205. 
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13C NMR (CDCl3, 101 MHz) 
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13C NMR (CDCl3, 101 MHz) 
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DEPT-135 NMR (CDCl3, 101 MHz) 
1H COSY NMR (CDCl3, 400 MHz) 
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1H NMR (CDCl3, 400 MHz) 
 
6c 
 
13C NMR (CDCl3, 101 MHz) 
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1H NMR (CDCl3, 400 MHz) 
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DEPT-135 NMR (CDCl3, 101 MHz) 
1H COSY NMR (CDCl3, 400 MHz) 
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1H-13C HSQC NMR (CDCl3, 400/101 MHz) 
S55 
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DEPT-135 NMR (CDCl3, 101 MHz) 
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1H-13C HSQC NMR (CDCl3, 400/101 MHz) 
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13C NMR (CDCl3, 101 MHz) 
S59 
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1H-13C HSQC NMR (CDCl3, 400/101 MHz) 
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1H NMR (CDCl3, 400 MHz) 
 
10c 
 
13C NMR (CDCl3, 101 MHz) 
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X-Ray Crystallography Data 
 
 
Scheme S2. Chemical derivatization of aziridine 5b to afford a regioisomeric mixture of 
crystalline amides 5b’ and 5b’’ 
 
  
 
 
 
  
5b’’ 5b’ 5b 
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Figure S1. Summary of X-ray diffraction data of amides 5b’ and 5b’’ 
 
 
 
Empirical formula: C23H21ClN2O 
Formula weight: 376.885 g/mol 
a: 9.444 Å 
b: 9.392 Å 
c: 44.328 Å 
α (alpha): 90.00° 
β (beta): 90.00° 
γ (gamma): 90.00° 
Volume: 3931.81 Å3 
Space group: Pbca 
Calculated density: 1.273 g/cm3 
Color, habit: colorless blade 
Z: 8 
Temperature: 100 K 
R(F): 0.0570 
Rw(F2): 0.1183 
S: 1.129 
 
 
Data deposited into the Cambridge Crystallographic Data Center (CCDC 1472245)
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3. Biological Annotation Methods 
 
Multiplexed cellular morphology (“Cell Painting”) imaging assay protocol 
 
We adapted our protocol from the one outlined by Gustafsdottir et al.6  and Wawer et al.7 1,000-
2,000 U-2 OS cells (ATCC, #HTB-96) were seeded in 50 µL media per well in 384-well clear-
bottom imaging plates. After incubating for 24 hours at 37 °C, compounds (6-point dose, 2-fold 
dilution, range: 3.125-100 µM assay concentration) were pin-transferred to the assay plates via a 
CyBi-Well robot. Treatments were performed in quadruplicate. Following transfer, the cells were 
allowed to incubate at 37 °C for an additional 24 hours. 
 
A 1 mM DMSO solution of MitoTracker Deep Red (Thermo Fisher, #M22426) and a 1 mg/mL 
dH2O solution of Wheat Germ Agglutinin (WGA), Alexa Fluor 594 conjugate (Thermo Fisher, 
#W11262) were prepared and combined in pre-warmed media to afford a staining solution (SS1) 
of 500 nM MitoTracker and 60 µg/mL WGA. After 40 µL of media were removed from each well 
of the assay plates (~10 µL remaining), 30 µL of SS1 were added to each well (~12 mL/plate). 
After incubating for 30 minutes at 37 °C, cells were fixed for 20 minutes at room temperature with 
16% aqueous paraformaldehyde (10 µL/well). Wells were then washed with 70 µL 1X HBSS 
(Thermo Fisher, #14065-056 [as 10X]). 
 
A 0.1% HBSS solution of Triton X-100 (Sigma-Aldrich, #T8787) was added to each well (30 
µL/well) to permeabilize the cells. After incubating for 15 minutes at room temperature, wells were 
washed with 70 µL 1X HBSS. 
 
A 1 mg/mL solution in 0.1 M aqueous sodium bicarbonate of Concanavalin A, Alexa Fluor 488 
conjugate (Thermo Fisher, #C11252) and a 1.5 mL/vial methanol solution of Phalloidin, Alexa 
Fluor 594 conjugate (Thermo Fisher, #A12381) were combined with a 10 mg/mL aqueous solution 
of Hoechst 33342 (Thermo Fisher, #H3570) and a 5 mM DMSO solution of SYTO 14 Green 
Fluorescent Nucleic Acid Stain (Thermo Fisher, #S7576) in 1X HBSS supplemented with 1% 
bovine serum albumin to afford a staining solution (SS2) of 0.025 mL Phalloidin/mL, 100 µg/mL 
Concanavalin, 5 µg/mL Hoechst, and 3 µM SYTO 14. 30 µL of SS2 were then added to each of 
the wells and the fixed cells were allowed to incubate at room temperature for 30 minutes. Wells 
were then washed with 70 µL 1X HBSS (no final aspiration) and the plates were thermally sealed 
with foil at 171 °C (4 seconds) for imaging. 
 
We captured images on an ImageXpress Micro epifluorescent microscope at 20x magnification 
over 5 fluorescent channels: DAPI (387/447 nm), GFP (472/520 nm), Cy3 (531/593 nm), 
TexasRed (562/642 nm), and Cy5 (628/692 nm). 9 sites were imaged per well. The first site of 
each well was used for lased-based auto-focus (DAPI channel). 
 
Table S2. Stains used in cell-painting experiment 
 
Stain Channel Name Excitation/Emission Wavelength (nm) Cellular Compartment(s) 
Hoechst DAPI 387/447 Nucleus 
Concanavalin A GFP 472/520 Endoplasmic reticulum 
SYTO 14 Cy3 531/593 Nucleolus 
WGA TexasRed 562/642 Golgi/plasma membrane 
Phalloidin TexasRed 562/642 F-actin 
MitoTracker DR Cy5 628/692 Mitochondria 
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Assay materials 
 
 U-2 OS cells (ATCC, #HTB-96) 
 Aurora 384-well black/clear bottom plates, imaging quality (Brooks, #1022-11330) 
 DMEM (Fisher Scientific, #MT10017CV) 
 FBS (Thermo Fisher, #10437028) 
 Penicillin/streptomycin (Fisher Scientific, #MT30002CI) 
 Hank’s Balanced Salt Solution, HBSS (Thermo Fisher, #14065-056) 
 MitoTracker Deep Red (Thermo Fisher, #M22426) 
 Wheat Germ Agglutinin, Alexa Fluor 594 conjugate (Thermo Fisher, #W11262) 
 Concanavalin A, Alexa Fluor 488 conjugate (Thermo Fisher, #C11252) 
 Phalloidin, Alexa Fluor 594 conjugate (Thermo Fisher, #A12381) 
 Hoechst33342 (Thermo Fisher, #H3570) 
 SYTO 14 green fluorescent nucleic acid stain (Thermo Fisher, #S7576) 
 Paraformaldehyde 16%, methanol free (Electron Microscopy Sciences, #15710-S) 
 Triton X-100 (Sigma-Aldrich, #T8787) 
 Bovine serum albumin 
 DMSO (Molecular Biology grade) 
 Methanol 
 Sodium bicarbonate 
 ImageXpress Micro (Molecular Devices) 
 
 
Assay timeline/overview 
 
Day One 
 
 Plate cells at 1,000-2,000 cells/50 µL per well (~30,000 cells/mL) in 
DMEM/10% FBS/1% PS 
 Grow overnight at 37 °C 
 
Day Two 
 
 Prepare reagents and stock solutions 
 Pin compounds 
 Treat for 24 hours at 37 °C 
 
Day Three 
 
 Prepare SS1 and SS2 
 Remove media from assay plates and add SS1; incubate for 30 minutes 
at 37 °C 
 Fix cells for 20 minutes at room temperature 
 Wash; permeabilize cells for 15 minutes at room temperature 
 Wash and add SS2; incubate for 30 minutes at room temperature 
 Wash (no final aspiration) and seal plates 
 Capture images (several hours per plate) 
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4. Data Processing and Analysis 
 
Image analysis and data processing  
 
We used the CellProfiler8 software pipelines9 provided by the Broad Institute Imaging Platform 
to process the raw images and obtain the morphological features used in subsequent analyses. 
First, the images were corrected for uneven illumination. Then, CellProfiler software (version 
2.1.1) was used to locate and segment cells into nuclei and cytoplasm, after which the size, 
shape, texture, intensity, local density, and radial distribution were measured for nuclei, 
cytoplasm, and entire cells. To obtain profiles for each compound, these cell-morphology 
features of compound-treated cells were averaged per well and then normalized by calculating 
robust z-scores based on the population of individual DMSO-treated cells found on the same 
plate. That is, the feature values were subtracted by the median value of the DMSO-treated 
cells, and then divided by the median absolute deviation of the DMSO-treated population. 
 
 
Biological profiles 
 
The “spectra” provided below are graphical representations of the biological profiles (i.e., vector 
of z-scores corresponding to the 1,140 cellular features) for each compound treatment condition 
(e.g. 5c at 50 M) compared to DMSO. Each point on the spectrum represents a single cellular 
feature and its associated z-score (depicted by its y-value). Adjacent points are connected by a 
line for ease of viewing. Each replicate (4 per treatment condition) is represented by a different 
color (orange, blue, green, and gray). 
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Compound activity calculation 
 
To determine the compound activities, we calculated the Mahalanobis distances of each 
compound profile from the associated populations of vehicle-treated well profiles. The profiles 
for all replicates of a compound were first combined with the corresponding DMSO-control wells 
into a matrix of dimensions m x n, where the rows m represent the individual wells and the 
columns n represent the profiling features. Principal component analysis was performed on this 
matrix to obtain a new matrix P with the principal components as the columns. For each of these 
matrices, the first q principal components were taken that were capable of explaining at least 
90% of the variance. This matrix P was separated into treatment and control matrices and for 
each part a covariance matrix was calculated. Each of the two covariance matrices (treatment 
and control) was weighted by the number of samples in each matrix, and the sum of the 
resulting matrices was used to calculate the Mahalanobis distance. 
 
 
Principal moment-of-inertia (PMI) calculations 
 
To calculate the principal moments of inertia, we first used Pipeline Pilot (version 8.5)10 to 
determine the most stable conformations (up to 5 each) for each of the 30 compounds using 
Dreiding force field for conformer calculation (ChemAxon 3D Conformers plugin).11 The PMIs 
were then calculated using the R package “Rcpi” (version 1.4.0)12 and the values were ordered 
from smallest to greatest as I1, I2, and I3. The ratios I1/I3 and I2/I3 were taken as the coordinates 
of the PMI plot. 
 
 
Heat map generation and clustering 
 
The heat map was generated using the pairwise Pearson correlations between each compound 
profile-compound profile pair. The profile for each compound was taken to be the average of 
each of its doses for all replicates. The correlation distance between each pair of compounds 
was taken to be (1 − Pearson coefficient). These distances were used to hierarchically cluster 
the compounds (using complete linkage) to provide the dendrograms shown on the correlation 
heat map. 
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